| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 472.3 | 419.8 | 535.9 |
| Other income | 4.4 | 2.8 | 3.3 |
| Total income | 476.7 | 422.6 | 539.2 |
| Profit before exceptional items & tax | 137.9 | 83.0 | 165.3 |
| Profit before tax | 137.9 | 83.0 | 165.3 |
| Net profit | 102.6 | 61.7 | 119.5 |
| Operating margin | 28.9% | 19.6% | 30.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -14.10% |
|---|---|
| Net profit, quarter on quarter | +66.30% |
| Revenue, year on year | -11.90% |
NSE results filing, NSE: SANOFI. Figures extracted from the filing.
Sanofi India Ltd: key numbers
- Share price
- ₹3,140.20
- Market cap
- ₹7,232 Cr
- Revenue (annual)
- ₹1,837 Cr
- Net profit (annual)
- ₹326.7 Cr
- P/E (TTM)
- 22.3×Sector 50.4×
- Promoter holding
- 60.40%+0.00% QoQ
- FII holding
- 5.69%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sanofi India Ltd
All →Sanofi India Legal & Regulatory
Sanofi India received a GST show cause notice alleging excess input tax credit claims. The total demand, including interest, is Rs. 23.74 Crore.
- Value
- ₹23.74 Cr
- From
- Commercial Tax Officer (Audit)-6.1, DGSTO-6, Bengaluru
Sanofi India Promoter Buying (Off-Market)
Sanofi Healthcare India acquired 3,500,000 equity shares (15.20%) of Sanofi India Limited via an inter-se promoter group transfer. The transaction was executed as a block deal.
- Promoter stake change
- +15.20%
Sanofi India Promoter Selling (Off-Market)
Hoechst GmbH transferred 3,500,000 shares of Sanofi India Limited to Sanofi Healthcare India Private Limited. This inter-se promoter group transfer represents a 15.20% stake.
Sanofi India Legal & Regulatory
Sanofi India disclosed that the State Tax Officer, Tiruvallur dropped a ₹1.07 Crore GST demand for FY 2022-23. The company confirmed no material financial or operational impact.
- Value
- ₹1.07 Cr
Sanofi India Promoter Buying (Off-Market)
Sanofi Healthcare India Private Limited, a promoter group entity, proposed an inter-se transfer of up to 3,500,000 shares from Hoechst GmbH. This transaction qualifies for open offer exemption.
- Promoter stake change
- +15.20%
Sanofi India Legal & Regulatory
The Supreme Court dismissed Sanofi India's petition to quash criminal proceedings. No penalty or operational restriction is imposed on the company at this stage.